High Outlier
Strength
.75 mg/1
Manufacturer
Novartis Pharmaceuticals CorporationNDC
00078041520
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Last Updated
1/3/2020
Active Ingredients
EVEROLIMUSApproval Type
New Drug (NDA)
FDA Application
NDA021560On Market Since
4/22/2010
Pharmacological Classes
Cytochrome P450 2D6 Inhibitors
Cytochrome P450 3A4 Inhibitors
Decreased Immunologic Activity
Kinase Inhibitor
Protein Kinase Inhibitors
mTOR Inhibitor Immunosuppressant
mTOR Inhibitors
Related Drugs
Same classification
TIAZAC ER 180 MG CAPSULE
Brand
00187261330•Bausch Health US LLC
$1.5060
per EA
TIAZAC ER 180 MG CAPSULE
Brand
00187261390•Bausch Health US LLC
$1.5060
per EA
MYRBETRIQ ER 8 MG/ML SUSP
Brand
00469502099•Astellas Pharma US, Inc.
$2.2097
per ML
TIAZAC ER 360 MG CAPSULE
Brand
00187261630•Bausch Health US LLC
$2.7628
per EA
TIAZAC ER 360 MG CAPSULE
Brand
00187261690•Bausch Health US LLC
$2.7628
per EA
NEORAL 25 MG GELATIN CAPSULE
Brand
00078024615•Novartis Pharmaceuticals Corporation
$2.8879
per EA
KALETRA 80 MG-20 MG/ML SOLN
Brand
00074395646•AbbVie Inc.
$3.1186
per ML
CARDIZEM LA 120 MG TABLET
Brand
00187204530•Bausch Health US LLC
$3.6467
per EA
CARDIZEM LA 120 MG TABLET
Brand
00187204590•Bausch Health US LLC
$3.6467
per EA
CARDIZEM LA 180 MG TABLET
Brand
00187204630•Bausch Health US LLC
$3.8314
per EA